sovaldi 400 mg tableta recubierta
biotoscana farma de peru s.a.c. - sofosbuvir; - tableta recubierta - por vial 1.00 tab - sofosbuvir
sofosbuvir
natco pharma limited. - sofosbuvir - tableta revestida - 400 mg
pemutol 400mg comprimido recubierto
tecnofarma s.a. - droguerÍa - comprimido recubierto - por comprimido - - sofosbuvir
cosopt® 20mg/ml + 5mg/ml solucion oftalmica
farmaceutica continental e.i.r.l. - clorhidrato de dorzolamida; maleato de timolol; - solucion oftalmica - por ovulo - timolol, combinaciones
gemcitabina
fresenius kabi oncology limited - gemcitabina (eq. a 227,72 mg o 1138,6 mg de clorhidrato de gemcitabina) - polvo estéril liofilizado para inyección iv - 200 mg; 1000 mg
dacogen
janssen cilag farmaceutica s.a. - decitabina - polvo liofilizado para infusion intravenosa - decitabina 50 mg
deferoxim-f 250 250mg tableta dispersable
world drug pharmaceutical s.a.c. - droguerÍa - tableta dispersable - por tableta - - deferasirox
deferoxim-f 500 500mg tableta dispersable
world drug pharmaceutical s.a.c. - droguerÍa - tableta dispersable - por tableta - - deferasirox
sarclisa
sanofi winthrop industrie - isatuximab - mieloma múltiple - agentes antineoplásicos - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
tenofovir disoproxil fumarato + emtricitabina 300mg+200mg tableta recubierta
laboratorios ac farma s.a. - laboratorio - tableta recubierta - por tableta - - tenofovir disoproxiol y emtricitabina